Pulmonary Arterial Hypertension Market, By Drug Class (PDE-5 Inhibitors, Endothelin Receptor Antagonists (ERAs), SGC Stimulators, Prostacyclin & Prostacyclin Analogs), By Type (Generics, Branded), By Route of Administration (Inhalational, Intravenous/Subcutaneous, Oral), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034

Pulmonary Arterial Hypertension (PAH)  Market is the form of broader condition called as pulmonary hypertension, where the increased pressure in vessels are caused by obstruction in small arteries of lungs.

Growing Prevalence of Pulmonary Hypertension to fuel market growth

Growing prevalence of pulmonary hypertension (PH) has become a major factor in target market growth. The increased PH-related mortality is driven by WHO (World Health Organization) groups 2 and 3. Rising adoption of unhealthy lifestyle and consumption of processed food across globe has given rise in chronic diseases which in turn, facilitated the demand for Pulmonary Arterial Hypertension market growth.

For instance, according to CDC WONDER (Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research), the cause of death database for study of age-standardized mortality rates related to PH in United States from 2003 to 2020 is as follows, the total of 126,526 deaths recorded from PH in between 2003 and 2020 and according to study period, the PH-related ASMR was increased from 17.81 per million of population in 2003 to 23.89 million in 2020 with change of percentage of +34%.

Restrains:

However, high cost of PAH drugs and therapies and side-effects of these medications has hampered the demand for Pulmonary Arterial Hypertension Market growth.

Pulmonary Arterial Hypertension Market Segmentation:

Pulmonary Arterial Hypertension Market is segmented based on Drug Class, Type, Route of Administration and Region.

Drug Class Insight

On the basis of Drug Class, Pulmonary Arterial Hypertension Market is segmented into PDE-5 Inhibitors, Endothelin Receptor Antagonists (ERAs), SGC Stimulators, Prostacyclin & Prostacyclin Analogs.

Type Insights

On the basis of Type, Pulmonary Arterial Hypertension Market is segmented into Generics, Branded.

Route of Administration Insights

On the basis of Route of Administration, Pulmonary Arterial Hypertension Market is segmented into Inhalational, Intravenous/Subcutaneous, Oral.

Pulmonary Arterial Hypertension Market Regional Insights:

On region the Pulmonary Arterial Hypertension Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

North America market is estimated to witness a significantly high revenue share over the forecast period due to rising prevalence of pulmonary hypertension, continuous technological development, increased awareness among people and robust healthcare infrastructure coupled with advanced diagnostic equipment.

Asia Pacific market is estimated to witness a fastest revenue share over the forecast period due to growing population, developing healthcare infrastructure, presence of major pharmaceutical companies such as Cipla Inc., who received FDA (Food and Drug Administration) approval for Ambrisentan Tablets to treat pulmonary arterial hypertension.

Recent Development:

             The New Launched Product News,

• In May 2023, The Janssen Pharmaceutical Company submitted its new drug application to U.S. FDA (Food and Drug Administration) for seeking approval of an investigational single tablet combination therapy of Tadalafil and Macitentan for treating patients with PAH (Pulmonary Arterial Hypertension).

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034.

The key players operating the Pulmonary Arterial Hypertension Market includes, United Therapeutics Corporation, Johnson & Johnson, Bayer, Gilead Sciences Inc., GlaxoSmithKline, Lupin Pharmaceuticals Inc., Novartis, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries, Inc., Viatris Inc., and others.

• United Therapeutics Corporation
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Johnson & Johnson
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

• Bayer
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Gilead Sciences Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• GlaxoSmithKline
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Lupin Pharmaceuticals Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Novartis
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Sun Pharmaceutical Industries, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Viatris Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies

1. The Last Word
   • Future Impact
   • About Us
   • Contact

1. Research Objective and Assumption
   • Preface
   • Research Objectives
   • Study Scope
   • Years Considered for the study
   • Assumptions
   • Abbreviations
2. Research Methodology
   • Research data
   • Primary Data
     • Primary Interviews
     • Primary Breakdown
     • Key data from Primary Sources
     • Key Thickness Insights
   • Secondary Data
     • Major Secondary Sources
     • Secondary Sources
   • Market Estimation
   • Top-Down Approach
     • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
   • Bottom-Up Approach
     • Approach for estimating market share by Bottom-up Analysis (Demand Side)
   • Market Breakdown and Data Triangulation
   • Research Assumptions
3. Market Purview
   • Executive Summary
   • Key Findings—Global Outlook for medical carts Strategies
     • Key Questions this Study will Answer
     • Market Snippet, By Drug Class
     • Market Snippet, By Type
     • Market Snippet, By Route of Administration
     • Market Snippet, By Region
   • Opportunity Map Analysis
   • Executive Summary—3 Big Predictions
4. Market Dynamics, Regulations, and Trends Analysis
   • Market Dynamics
     • Drivers
     • Restrains
     • Market Opportunities
     • Market Trends
   • DR Impact Analysis
   • PEST Analysis
   • Porter’s Five Forces Analysis
   • Opportunity Orbit
   • Market Investment Feasibility Index
   • Macroeconomic Factor Analysis
5. Pulmonary Arterial Hypertension Market, By Drug Class, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• PDE-5 Inhibitors
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Endothelin Receptor Antagonists (ERAs)
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• SGC Stimulators
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Prostacyclin & Prostacyclin Analogs
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

1. Pulmonary Arterial Hypertension Market, By Type, Forecast Period up to 10 Years, (US$ Bn)
   • Overview                                      
     • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
     • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
     • Segment Trends
   • Generics
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
   • Branded
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
2. Pulmonary Arterial Hypertension Market, By Route of Administration, Forecast Period up to 10 Years, (US$ Bn)
   • Overview                                      
     • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
     • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
     • Segment Trends
   • Inhalational
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
   • Intravenous/Subcutaneous
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
   • Oral
     • Overview
     • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
3. Pulmonary Arterial Hypertension Market, By Region, Forecast Period up to 10 Years, (US$ Bn)
   • Overview
     • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
     • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
     • Regional Trends
   • North America
     • Market Size and Forecast (US$ Bn), By Drug Class, Forecast Period up to 10 Years
     • Market Size and Forecast (US$ Bn), By Type, Forecast Period up to 10 Years
     • Market Size and Forecast (US$ Bn), By Route of Administration, Forecast Period up to 10 Years
     • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
       • U.S.
       • Canada
   • Europe
     • Market Size and Forecast (US$ Bn), By Drug Class, Forecast Period up to 10 Years
     • Market Size and Forecast (US$ Bn), By Type, Forecast Period up to 10 Years
     • Market Size and Forecast (US$ Bn), By Route of Administration, Forecast Period up to 10 Years
     • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
       • UK
       • France
       • Germany
       • Russia
       • Italy
       • Rest of Europe
   • Asia Pacific
     • Market Size and Forecast (US$ Bn), By Drug Class, Forecast Period up to 10 Years
     • Market Size and Forecast (US$ Bn), By Type, Forecast Period up to 10 Years
     • Market Size and Forecast (US$ Bn), By Route of Administration, Forecast Period up to 10 Years
     • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
       • India
       • Japan
       • South Korea
       • China
       • Rest of Asia Pacific
   • Latin America
     • Market Size and Forecast (US$ Bn), By Drug Class, Forecast Period up to 10 Years
     • Market Size and Forecast (US$ Bn), By Type, Forecast Period up to 10 Years
     • Market Size and Forecast (US$ Bn), By Route of Administration, Forecast Period up to 10 Years
     • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years

• Brazil
• Mexico
• Rest of Latin America
• Middle East & Africa
  • Market Size and Forecast (US$ Bn), By Drug Class, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Type, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Route of Administration, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
• GCC
• Israel
• South Africa
• Rest of Middle East

1. Competitive Landscape
   • Heat Map Analysis
   • Market Presence and Specificity Analysis